Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TMEM97 | Q5BJF2 | 2/20 | 0.47 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.47 |
| ▸ | LTA4H | P09960 | 7/20 | 0.43 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.41 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.41 |
| ▸ | HTR1A | P08908 | 2/20 | 0.40 |
| ▸ | HTR7 | P34969 | 2/20 | 0.40 |
| ▸ | KCNH2 | Q12809 | 4/20 | 0.40 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.40 |
| ▸ | DRD2 | P14416 | 1/20 | 0.40 |
| ▸ | MCHR1 | Q99705 | 2/20 | 0.39 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.39 |
| ▸ | MAOB | P27338 | 1/20 | 0.39 |
| ▸ | KDR | P35968 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13499258 | 0.89 | HTR1A (0.48) | TMEM97SIGMAR1LTA4HCHRM2CHRM3 | |
| SCHEMBL13499473 | 0.87 | KDM1A (0.49) | TMEM97SIGMAR1LTA4HCHRM2CHRM3 | |
| SCHEMBL13499332 | 0.85 | TMEM97 (0.47) | TMEM97SIGMAR1LTA4HCHRM2CHRM3 | |
| SCHEMBL13499437 | 0.83 | TMEM97 (0.47) | TMEM97SIGMAR1LTA4HCHRM2CHRM3 | |
| SCHEMBL13499470 | 0.82 | TMEM97 (0.40) | TMEM97SIGMAR1LTA4HCHRM2CHRM3 | |
| SCHEMBL13499369 | 0.81 | HTR1A (0.48) | TMEM97SIGMAR1LTA4HCHRM2CHRM3 | |
| SCHEMBL13499365 | 0.73 | HTR1A (0.50) | TMEM97SIGMAR1LTA4HCHRM2CHRM3 | |
| SCHEMBL13633427 | 0.73 | HTR1A (0.45) | LTA4HHTR1AHTR7KCNH2DRD2 | |
| SCHEMBL13499330 | 0.73 | HTR1A (0.49) | TMEM97SIGMAR1LTA4HCHRM2CHRM3 | |
| SCHEMBL13499337 | 0.73 | KCNA5 (0.47) | TMEM97SIGMAR1LTA4HCHRM2CHRM3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100029620-A1 | SUBSTITUTED TRIAZOLINE, TETRAZOLONE AND IMIDAZOLONE DERIVATIVES FOR USE AS A MEDICINE | JANSSEN PHARMACEUTICA N.V. | 2010-02-04 | — | — | US | disclosed |
| US-20100029620-A1 | SUBSTITUTED TRIAZOLINE, TETRAZOLONE AND IMIDAZOLONE DERIVATIVES FOR USE AS A MEDICINE | JANSSEN PHARMACEUTICA N.V. | 2010-02-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100029620-A1 | SUBSTITUTED TRIAZOLINE, TETRAZOLONE AND IMIDAZOLONE DERIVATIVES FOR USE AS A MEDICINE | ADRA2C, ADRB2, CHRNA5 | TMEM97 139/4885SIGMAR1 58/4885LTA4H 3480/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.